GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Cyclically Adjusted Price-to-FCF

CTI BioPharma (FRA:CEPS) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CTI BioPharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CTI BioPharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Cyclically Adjusted Price-to-FCF Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CTI BioPharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CTI BioPharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Cyclically Adjusted Price-to-FCF falls into.



CTI BioPharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CTI BioPharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, CTI BioPharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.221/127.3478*127.3478
=-0.221

Current CPI (Mar. 2023) = 127.3478.

CTI BioPharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 -1.097 98.518 -1.418
201309 -1.052 98.790 -1.356
201312 0.560 98.326 0.725
201403 -1.059 99.695 -1.353
201406 -0.899 100.560 -1.138
201409 -0.274 100.428 -0.347
201412 0.189 99.070 0.243
201503 -1.276 99.621 -1.631
201506 -1.266 100.684 -1.601
201509 -1.225 100.392 -1.554
201512 -0.891 99.792 -1.137
201603 -0.745 100.470 -0.944
201606 -0.825 101.688 -1.033
201609 -0.422 101.861 -0.528
201612 -0.493 101.863 -0.616
201703 -0.290 102.862 -0.359
201706 0.018 103.349 0.022
201709 -0.406 104.136 -0.496
201712 -0.207 104.011 -0.253
201803 -0.040 105.290 -0.048
201806 -0.187 106.317 -0.224
201809 -0.178 106.507 -0.213
201812 -0.192 105.998 -0.231
201903 -0.053 107.251 -0.063
201906 -0.111 108.070 -0.131
201909 -0.088 108.329 -0.103
201912 -0.178 108.420 -0.209
202003 -0.151 108.902 -0.177
202006 -0.115 108.767 -0.135
202009 -0.131 109.815 -0.152
202012 -0.119 109.897 -0.138
202103 -0.185 111.754 -0.211
202106 -0.158 114.631 -0.176
202109 -0.186 115.734 -0.205
202112 -0.272 117.630 -0.294
202203 -0.273 121.301 -0.287
202206 -0.176 125.017 -0.179
202209 -0.128 125.227 -0.130
202212 -0.114 125.222 -0.116
202303 -0.221 127.348 -0.221

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CTI BioPharma  (FRA:CEPS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CTI BioPharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (FRA:CEPS) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines